VitaDAO is on a roll with these DAO2DAO relationships. Questions/observations:
-
Is the 50k amount being paid out in tranches contingent on the fulfilment of some pre-meditated milestones. If yes, what are these milestones and what does the expected payout schedule look like. Also, what constitutes failure as far as payouts are concerned?
-
What constitutes failure in general? Under what circumstances will the DAO be considered defunct?
-
What is AthenaDAO’s valuation here and what % equity will VitaDAO own? Are we modelling this engagement after the WAGMI grant by going for a 6.9% stake
-
What is our DD strategy. Do we evaluate the team behind the project and calculate risk and diversification, among other things, that VitaDAO accrues? The team bit may be easy here as most core team members at AthenaDAO are VitaDAO contributors. What is our risk mitigation strategy in addition to (practically) incubating AthenaDAO
-
What is the benefit of creating a separate DAO as opposed to funding women’s reproductive health research and drug discovery through VitaDAO. Is the focus area so dissimilar that it warrants its own DAO and, at the same time, somewhat overlapping so that collaborative funding can occur in the future? One benefit I can think of is access to grants that are strictly for organizations working on women’s reproductive health and also, in this case, for women founders. We may have to engage AthenaDAO’s core team for a response here